MARKET

XBIO

XBIO

Xenetic Biosciences Inc
NASDAQ
2.710
-0.180
-6.23%
Closed 18:23 07/08 EDT
OPEN
2.830
PREV CLOSE
2.890
HIGH
2.830
LOW
2.671
VOLUME
17.20K
TURNOVER
0
52 WEEK HIGH
13.93
52 WEEK LOW
1.900
MARKET CAP
6.21M
P/E (TTM)
-2.1818
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XBIO last week (0629-0703)?
Weekly Report · 3d ago
Weekly Report: what happened at XBIO last week (0622-0626)?
Weekly Report · 06/29 09:32
Weekly Report: what happened at XBIO last week (0615-0619)?
Weekly Report · 06/22 09:36
Weekly Report: what happened at XBIO last week (0608-0612)?
Weekly Report · 06/15 09:37
Weekly Report: what happened at XBIO last week (0601-0605)?
Weekly Report · 06/08 09:35
Xenetic Biosciences Announces That Its Collaboration Partner PeriNess Received Israeli Ministry Of Health Approval To Conduct An Exploratory Clinical Study Of Combination Systemic DNase I With Anti-CD19 CAR T Cells In Large B Cell Lymphoma Patients
Benzinga · 06/04 12:51
Xenetic partner PeriNess receives Israeli MOH approval for DNase I study
TipRanks · 06/04 12:47
Xenetic partner launches Israeli investigator-led trial of DNase I with anti-CD19 CAR T in large B-cell lymphoma
PUBT · 06/04 12:46
More
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

Webull offers Xenetic Biosciences Inc stock information, including NASDAQ: XBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XBIO stock methods without spending real money on the virtual paper trading platform.